At convEyXO, we’re dedicated to pioneering new treatments that benefit patients.

We produce exosomes from our immortalized cell line, which we load with a selected RNA based on the indication to enhance their native anti-inflammatory and regenerative properties.

Our pipeline represents our commitment to transforming patient care, with programs in discovery through pre-clinical development to clinic in early 2027.

We develop a proprietary RNA-enhanced exosomes-based therapeutic portfolio to target osteoarthritis and dermatological conditions, with high unmet medical needs.

We leverage our technology platform to target a wider range of treatments through strategic partnerships.